You are here

Current Projects

Looking for a specific type of study? Finding the right fit is simple:
 1. Select your criteria below
 2. Press submit to view your results

The following projects are currently open and enrolling volunteers. These studies were evaluated and approved by the research team at Dr. Susan Love Research Foundation and members of our external Scientific Advisory Committee, comprised of researchers, clinicians, and advocates.

If you would like to learn about the studies we recruited for in the past, please click here.

Researcher: Christine Miaskowski, PhD, RN, University of California, San Francisco
Broadcast date: April 25, 2017

This study is designed to identify both signs and symptoms of breast cancer-related lymphedema and genetic factors that predict whether patients are at increased risk for developing lymphedema. The researchers intend to use the results to develop and test new approaches to prevent or reduce the risk of lymphedema developing following breast cancer treatment.

Researcher: Steven Narod, MD, Women's College Research Institute, Toronto, Ontario, Canada
Broadcast date: March 15, 2017

Genetic and non-genetic factors are believed to influence whether a woman with a BRCA1, BRCA2, and/or PALB2 mutation goes on to develop breast and/or ovarian cancer. The study is trying to identify which hormonal, reproductive, and lifestyle factors may increase cancer risk in this high-risk group.

Researcher: Janice Kiecolt-Glaser, Ph.D., The Ohio State University Institute, Columbus, OH
Broadcast date: September 7, 2016

The purpose of this study is to investigate the relationship between your cardiovascular fitness and your body’s immune response, as both may be related to fatigue (tiredness), mood, pain sensitivity, memory, and concentration—known side effects of cancer and its treatments. By learning if people with better cardiovascular fitness have lower inflammation, researchers will be able to discover whether and how regular exercise benefits breast cancer survivors.

Researcher: Heather Greenlee, ND, PhD, Columbia University, New York
Broadcast date: June 1, 2016

The purpose of this study is to test the effectiveness of Mi Vida Saludable (My Healthy Life), a program designed to help Latina/Hispanic breast cancer survivors eat a healthy diet and be physically active. The Mi Vida Saludable program includes four weeks of hands-on and in-person nutrition and physical activity education classes and 11 months of electronic communication via text messaging, emails, and a website. Participants will track their physical activity with a Fitbit Zip, which they keep at the end of the study.

Researcher: Cynthia Ma, MD, PhD, Washington University, St. Louis, MO
Broadcast date: March 19, 2014

The purpose of this study is to see whether neratinib is effective in treating HER2-negative metastatic tumors that have a specific type of genetic mutation (ERBB2). The first part of this study is a preliminary screening. During this part of the study, your tumor tissue will be tested to see if it has the specific mutation the researchers are looking for. If your tumor has the mutation, you will be given more information about the main research study, which is investigating the effectiveness of neratinib.

Researcher: Susan Neuhausen, PhD, City of Hope, Duarte, CA
Broadcast date: January 22, 2014

The goal of this study is to learn more about breast cancer in Hispanic women by studying Hispanic women with breast cancer and Hispanic women who have never had breast cancer. The research team has enrolled Hispanic women with breast cancer for the study. Now, they need Hispanic women who have never had any type of cancer (skin cancers are okay).

If you enroll in this study, you will NOT receive any individual genetic test results. Every participant is assigned a coded study number, and no genetic information is connected to her name. There is no way for the researchers to ever tell you anything about your test results. By taking part in this study, you will help researchers help future generations of Hispanic Women.